SUCCESSFULLY LITIGATING METHOD OF USE PATENTS IN THE U.S.
|
|
- Rosamund Lane
- 6 years ago
- Views:
Transcription
1 SUCCESSFULLY LITIGATING METHOD OF USE PATENTS IN THE U.S. The 10 th Annual Generics, Supergenerics, and Patent Strategies Conference London, England May 16, 2007 Provided by: Charles R. Wolfe, Jr. H. Keeto Sabharwal Blank Rome LLP Copyright 2007, by Charles R. Wolfe, Jr. and Brian Wm. Higgins
2 Today s s Presentation Introduction Overview Legal Framework Pre-Litigation Strategy Proving Infringement: Method of Use Patents Remedies: Infringement of Method of Use Patents Questions? 2
3 Introduction 3
4 Overview Legal Framework New Drug Application Patent Information Drug Products (API, polymorphs, formulations) Method of Use (NDA use, non-nda use) Excluded subject matter Timing 4
5 Overview Legal Framework (con( con t) NDA Patent Information: The applicant shall file with the application the patent number and the expiration date of any patent which claims the drug for which the applicant submitted the application or which claims a method of using such drug and with respect to which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner engaged in the manufacture, use, or sale of the drug. 21 U.S.C. 355(b)(1) 5
6 Overview Legal Framework (con( con t) NDA Patent Information for API (drug substance): For patents that claim the drug substance, the applicant shall submit information only on those patents that claim the drug substance that is the subject of the pending or approved application or that claim a drug substance that is the same as the active ingredient that is the subject of the approved or pending application. 21 C.F.R (b) 6
7 Overview Legal Framework (con( con t) NDA Patent Information for polymorph: For patents that claim a polymorph that is the same as the active ingredient described in the approved or pending application, the applicant shall certify in the declaration forms that the applicant has test data, as set forth in paragraph (b)(2) of this section, demonstrating that a drug product containing the polymorph will perform the same as the drug product described in the new drug application. 21 CFR (b) 7
8 Overview Legal Framework (con( con t) NDA Patent Information for formulation (drug product): For patents that claim a drug product, the applicant shall submit information only on those patents that claim a drug product, as is defined in 314.3, that is described in the pending or approved application. 21 CFR (b) 8
9 Overview Legal Framework (con( con t) NDA Patent information for method of use: For patents that claim a method of use, the applicant shall submit information only on those patents that claim indications or other conditions of use that are described in the pending or approved application. 21 CFR (b) 9
10 Overview Legal Framework (con( con t) Excluded Subject Matter Methods of manufacturing Packaging Metabolites Intermediates Process patents, patents claiming packaging, patents claiming metabolites, and patents claiming intermediates are not covered by this section, and information on these patents must not be submitted to FDA. 21 CFR (b) 10
11 Overview Legal Framework (con( con t) Timing: existing patents The applicant shall file with the application 21 U.S.C. 355(b) 11
12 Overview Legal Framework (con( con t) Timing: newly issued patents...after the filing date but before approval of the application, the applicant shall amend the application to include the information U.S.C. 355(b)... after an application is approved... within 30 days of the date of issuance of the patent. 21 CFR
13 Overview Legal Framework (con( con t) ANDA Patent Certification Paragraph I Paragraph II Paragraph III Paragraph IV Section VIII Statement (non-approved use) Timing 13
14 Overview Legal Framework (con( con t) ANDA Patent Certification An abbreviated application for a new drug shall contain (vii) a certification, in the opinion of the applicant and to the best of his knowledge, with respect to each patent which claims the listed drug referred to in clause (i) or which claims a use for such listed drug for which the applicant is seeking approval under this subsection. 21 U.S.C. 355(j)(2)(A)(vii) 14
15 Overview Legal Framework (con( con t) ANDA Paragraph I Patent Certification that such patent information has not been filed. 21 U.S.C. 355(j)(2)(A)(vii)(I) 15
16 Overview Legal Framework (con( con t) ANDA Paragraph II Patent Certification that such patent has expired. 21 U.S.C. 355(j)(2)(A)(vii)(II) 16
17 Overview Legal Framework (con( con t) ANDA Paragraph III Patent Certification of the date on which such patent will expire. 21 U.S.C. 355(j)(2)(A)(vii)(III) 17
18 Overview Legal Framework (con( con t) ANDA Paragraph IV Patent Certification that such patent is invalid or will not be infringed by the manufacture, use, or sale of the new drug for which the application is submitted. 21 U.S.C. 355(j)(2)(A)(vii)(IV) 18
19 Overview Legal Framework (con( con t) ANDA Section viii Statement Patent Certification... a method of use patent which does not claim a use for which the applicant is seeking approval under this subsection, a statement that the method of use patent does not claim such a use. 21 U.S.C. 355(j)(2)(A)(viii) 19
20 Overview Legal Framework (con( con t) ANDA Patent Certification: Paragraph IV Notice An applicant that makes a certification described in [Paragraph IV]... will give notice as required by this subparagraph. 21 U.S.C. 355(j)(2)(B)(i) 20
21 Overview Legal Framework (con( con t) ANDA Patent Certification: Paragraph IV Notice To whom given? (I) each owner of the patent... (II) the holder of the approved application U.S.C. 355(j)(2)(B)(iii) 21
22 Overview Legal Framework (con( con t) ANDA Patent Certification: Paragraph IV Notice When given? (I)...not later than 20 days after date of the postmark on the notice [form FDA]...that the application has been filed... (II)...at the time at which the applicant submits the amendment or supplement 21 U.S.C. 355(j)(2)(B)(ii) 22
23 Overview Legal Framework (con( con t) Consequences 30 month stay Drug Product Method of Use 23
24 Overview Legal Framework (con( con t) Paragraph IV litigation brought by patent owner before the expiration of 45 days after... notice... is received... an action is brought for infringement... the approval shall be made effective upon the expiration of the thirty month period beginning on the date of the receipt of the notice U.S.C. 355(j)(5)(B)(iii) 24
25 Overview Legal Framework (con( con t) Paragraph IV litigation brought by ANDA applicant i.e., Civil action to obtain patent certainty No action may be brought...for declaratory judgment with respect to a patent which is the subject of the certification...unless 25
26 Overview Legal Framework (con( con t) (aa) the 45-day period...has expired (bb) neither the owner of such patent nor the holder of the approved application...brought a civil action...for infringement (cc) in any case in which the notice...relates to non-infringement, the notice was accompanied by [an offer of confidential access] 21 U.S.C. 355(j)(5)(C)(i) 26
27 Pre-Litigation Strategy Guarding against willful infringement A finding of willful infringement is made after considering the totality of the circumstances. Knorr-Bremse Systeme Fuer Nutzfahrzeuge GmbH v. Dana Corp., 383 F.3d 1337, (Fed. Cir. 2004) (en banc). 27
28 Pre-Litigation Strategy Guarding against willful infringement (cont.) [W]here, as here, a potential infringer has actual notice of another's patent rights, he has an affirmative duty to exercise due care to determine whether or not he is infringing, including the duty to seek and obtain competent legal advice from counsel before the initiation of any possible infringing activity. Underwater Devices, Inc. v. Morrison- Knudsen Co., 717 F.2d 1380, (Fed. Cir. 1983) 28
29 Pre-Litigation Strategy Adverse inference (old rule): [A] court must be free to infer that either no opinion was obtained or, if an opinion were obtained, it was contrary to the infringer's desire to initiate or continue its use of the patentee's invention. Fromson v. Western Litho Plate & Supply Co., 853 F.2d 1568, (Fed. Cir. 1988) 29
30 Pre-Litigation Strategy Adverse inference (new rule): [T]he assertion of attorney-client and/or work-product privilege and the withholding of the advice of counsel shall no longer entail an adverse inference as to the nature of the advice. See Knorr-Bremse Systeme Fuer Nutzfahrzeuge GmbH v. Dana Corp., 383 F.3d 1337 (Fed. Cir. 2004) (en banc). 30
31 Pre-Litigation Strategy Waiver of Attorney Client Privilege The attorney-client privilege protects disclosure of communications between a client and his attorney. United States v. Zolin, 491 U.S. 554, 562 (1989) 31
32 Pre-Litigation Strategy Waiver of Attorney Client Privilege (cont.) [W]hen [defendant] chose to rely on the advice of in-house counsel, it waived the attorney-client privilege with regard to any attorney-client communications relating to the same subject matter, including communications with counsel other than in-house counsel, which would include communications with [outside counsel]. In re EchoStar Communications Corp., 78 USPQ2d 1676 (Fed. Cir. 2006) 32
33 Pre-Litigation Strategy Waiver of Attorney Work Product Unlike the attorney-client privilege, which protects all communication whether written or oral, work-product immunity protects documents and tangible things, such as memorandums, letters, and s. Judicial Watch, Inc. v. Dep't of Justice, 432 F.3d 366 (D.C. Cir. 2005) 33
34 Pre-Litigation Strategy Waiver of Attorney Work Product (cont.) Three categories of work product that are potentially relevant to the advice-ofcounsel defense: (1) documents that embody a communication between the attorney and client concerning the subject matter of the case, such as a traditional opinion letter - WAIVED 34
35 Pre-Litigation Strategy Waiver of Attorney Work Product (cont.) (2) documents analyzing the law, facts, trial strategy, and so forth that reflect the attorney's mental impressions but were not given to the client NOT WAIVED 35
36 Pre-Litigation Strategy Waiver of Attorney Work Product (cont.) (3) documents that discuss a communication between attorney and client concerning the subject matter of the case but are not themselves communications to or from the client WAIVED In re EchoStar Communications Corp., 78 U.S.P.Q.2d 1676 (Fed. Cir. 2006) 36
37 Pre-Litigation Strategy Declaratory Judgment Actions Applies to Paragraph IV certification If patentee/nda holder does not bring an infringement suit within 45 days after receiving notice, ANDA applicant may bring declaratory judgment civil action that the patent at issue is invalid or will not be infringed by the drug for which the ANDA was submitted. 21 U.S.C. 355(j)(5)(C) 37
38 Pre-Litigation Strategy Declaratory Judgment Actions (cont.) The [Federal Circuit s] reasonableapprehension-of-suit test [] conflicts with our [Supreme Court] decisions MedImmune, Inc. v. Genentech, Inc., 127 S. Ct. 764, 774 & n11 (2007) 38
39 Pre-Litigation Strategy Declaratory Judgment Actions (cont.) Actual controversy? Look at all the circumstances, but at least 3 needed: (1) Listing patents in OB (not enough by itself); (2) Submitting ANDA with P-IV; (3) Being sued by NDA/patent holder; Teva Pharmaceuticals USA Inc. v. Novartis Pharmaceuticals Corp., 82 U.S.P.Q.2d 1225 (Fed. Cir. 2007) 39
40 Pre-Litigation Strategy Declaratory Judgment Actions (cont.) Not available where seeking to have patent de-listed from OB Mylan Pharmaceuticals Inc. v. Thompson, 60 U.S.P.Q.2d 1576 (Fed. Cir. 2001) 40
41 Proving Infringement: Method of Use Patents Inducing infringement Whoever actively induces infringement of a patent shall be liable as an infringer. 35 U.S.C. 271(b) 41
42 Proving Infringement: Method of Use Patents (cont.) Inducing infringement (cont.) [D]ependent upon the existence of direct infringement Joy Techs., Inc. v. Flakt, Inc., 6 F.3d 770, 774 (Fed. Cir. 1993) Must establish intent (circumstantial evidence is allowed) Metabolite Labs. Inc. v. Labs. Corp. Am., 370 F.3d 1354, 1365 (Fed. Cir. 2004) 42
43 Proving Infringement: Method of Use Patents (cont.) Inducing infringement (cont.) For method or process patents, must shown that the direct infringer performed all process steps in the U.S. See NTP Inc. v. Research In Motion Ltd., 75 USPQ2d 1763 (Fed. Cir. 2005) 43
44 Proving Infringement: Method of Use Patents (cont.) Inducing infringement of pharma method of use patents A method of use patent holder may not sue an ANDA applicant for induced infringement of its patent, if the ANDA applicant is not seeking FDA approval for the use claimed in the patent and if the use claimed in the patent is not FDA-approved. Warner-Lambert Co. v. Apotex Corp., 65 U.S.P.Q.2d 1481 (Fed. Cir. 2003) 44
45 Proving Infringement: Method of Use Patents (cont.) Inducing infringement of pharma method of use patents (cont.) The mere filing of an ANDA is not itself evidence of direct infringement needed to satisfy an inducement claim; the patentee must still prove all elements of direct infringement Allergan Inc. v. Alcon Laboratories Inc., 66 U.S.P.Q.2d 1225 (Fed. Cir. 2003) 45
46 Proving Infringement: Method of Use Patents (cont.) Sources of proof inducement Direct infringement Testimony from doctors and patients Surveys Active inducement Labeling Promotional material 46
47 Proving Infringement: Method of Use Patents (cont.) Sources of proof inducement (cont.) Intent Admissions ( s) Marketing studies Financial projections 47
48 Remedies: Infringement of Method of Use Patents Preliminary Injunction Other than likelihood of success on the merits, the other factors relevant to decision to grant or deny a preliminary injunction are (1) irreparable harm if the injunction is not granted; (2) the balance of hardships between the parties; and (3) the public interest. Abbott Labs. v. Andrx Pharma. Inc., 81 U.S.P.Q.2d 1289 (Fed. Cir. 2007) 48
49 Remedies: Infringement of Method of Use Patents Permanent Injunction A patentee seeking a permanent injunction must satisfy a four-factor test before a court may grant such relief. (1) that it has suffered an irreparable injury; (2) that remedies available at law, such as monetary damages, are inadequate to compensate for that injury; 49
50 Remedies: Infringement of Method of Use Patents Permanent Injunction (cont.) (3) that, considering the balance of hardships between the plaintiff and defendant, a remedy in equity is warranted; and (4) that the public interest would not be disserved by a permanent injunction See ebay Inc. v. MercExchange LLC, 78 U.S.P.Q.2d 1577 (U.S. 2006) 50
51 Remedies: Infringement of Method of Use Patents Monetary damages (lost profits) The Panduit test requires that a patentee establish: (1) demand for the patented product; (2) absence of acceptable non-infringing substitutes; (3) manufacturing and marketing capacity to exploit the demand; and (4) the amount of profit it would have made. Rite-Hite Corp. v. Kelley Co., Inc., 56 F.3d 1538, 1545 (Fed. Cir. 1995) (en banc) (citing Panduit) 51
52 Remedies: Infringement of Method of Use Patents Monetary damages (reasonable royalty) A jury may award a patentee damages adequate to compensate for the infringement, but in no event less than a reasonable royalty for the use made of the invention by the infringer. 35 U.S.C
53 Remedies: Infringement of Method of Use Patents Exceptional cases Exceptional cases usually feature some material, inappropriate conduct related to the matter in litigation, such as willful infringement, fraud or inequitable conduct in procuring the patent, misconduct during litigation, vexatious or unjustified litigation, conduct that violates [FRCP] 11, or like infractions. Serio-US Indus. Inc. v. Plastic Recovery Tech. Corp., 80 U.S.P.Q.2d 1065 (Fed. Cir. 2006) 53
54 Questions? Contact Information Name: Charles R. Wolfe, Jr. Phone: Name: H. Keeto Sabharwal Phone:
55 Presenter Bios Charles Wolfe, Intellectual Property and Technology Practice Group Leader for Blank Rome, is a registered U.S. patent attorney with over thirty years of experience in U.S. patent law beginning as a patent examiner with the U.S. Patent and Trademark Office ( USPTO ). He has extensive experience representing clients before the USPTO and U.S. courts, including defending generic drug companies in Hatch-Waxman Paragraph IV litigations, which involved formulation and method of use patents. Keeto Sabharwal is a partner in the Intellectual Property and Technology Group for Blank Rome. For over 12 years, he has litigated patent cases in forums throughout the United States and abroad involving a variety of pharmaceutical, chemical and biotechnological products. In addition to Mr. Sabharwal s extensive litigation experience, he has advised pharmaceutical companies throughout the world as to licensing, due diligence and antitrust issues. 55
Infringement Assertions In The New World Order
Infringement Assertions In The New World Order IP Law360, October 17, 2007, Guest Column Author(s): Charles R. Macedo, Michael J. Kasdan Wednesday, Oct 17, 2007 The recent Supreme Court and Federal Circuit
More informationLitigation Webinar Series. Hatch-Waxman 101. Chad Shear Principal, San Diego
Litigation Webinar Series Hatch-Waxman 101 Chad Shear Principal, San Diego 1 Overview Hatch-Waxman Series Housekeeping CLE Contact: Jane Lundberg lundberg@fr.com Questions January 25, 2018 INSIGHTS Litigation
More informationFrom PLI s Program New Strategies Arising from the Hatch-Waxman Amendments #4888
From PLI s Program New Strategies Arising from the Hatch-Waxman Amendments #4888 New Strategies Arising From the Hatch-Waxman Amendments Practicing Law Institute Telephone Briefing May 12, 2004 I. INTRODUCTION
More informationNo IN THE EISAI CO. LTD AND EISAI MEDICAL RESEARCH, INC., TEVA PHARMACEUTICALS USA, INC., through its GATE PHARMACEUTICALS Division,
No. 10-1070 ~[~ 2 7 7.i~[ IN THE EISAI CO. LTD AND EISAI MEDICAL RESEARCH, INC., Petitioners, TEVA PHARMACEUTICALS USA, INC., through its GATE PHARMACEUTICALS Division, Respondent. ON PETITION FOR A WRIT
More informationUnited States Court of Appeals for the Federal Circuit
United States Court of Appeals for the Federal Circuit TEVA PHARMACEUTICALS USA, INC., THROUGH ITS GATE PHARMACEUTICALS DIVISION, Plaintiff-Appellant, v. EISAI CO., LTD. AND EISAI MEDICAL RESEARCH, INC.,
More informationRecent developments in US law: Remedies and damages for improper patent listings in the FDA s Orange Book
Daniel G. Brown is a partner in the New York law firm Frommer Lawrence & Haug, LLP, and practises extensively in the Hatch Waxman area. He has been practising in New York since 1993 in the patent and intellectual
More informationLife Sciences Industry Perspective on Declaratory Judgment Actions and Licensing Post-MedImmune. Roadmap for Presentation
Life Sciences Industry Perspective on Declaratory Judgment Actions and Licensing Post-MedImmune MedImmune: R. Brian McCaslin, Esq. Christopher Verni, Esq. March 9, 2009 clients but may be representative
More informationAn ANDA Update. June 2004 Bulletin 04-50
June 2004 Bulletin 04-50 If you have questions or would like additional information on the material covered in this Bulletin, please contact one of the authors: Mark R. Shanks 202.414.9201 mshanks@reedsmith.com
More informationCase 3:14-cv MLC-TJB Document Filed 07/24/15 Page 2 of 16 PageID: 1111 TABLE OF CONTENTS INTRODUCTION... 1 BACKGROUND...
Case 3:14-cv-02550-MLC-TJB Document 100-1 Filed 07/24/15 Page 1 of 16 PageID: 1110 Keith J. Miller Michael J. Gesualdo ROBINSON MILLER LLC One Newark Center, 19th Floor Newark, New Jersey 07102 Telephone:
More informationInjunctions for patent infringement after the ebay decision Fitzpatrick, Cella, Harper & Scinto
Injunctions for patent infringement after the ebay decision Fitzpatrick, Cella, Harper & Scinto This text first appeared in the IAM magazine supplement From Innovation to Commercialisation 2007 February
More informationCaraco V. Novo Nordisk: Antitrust Implications
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Caraco V. Novo Nordisk: Antitrust Implications Law360,
More informationSome Declaratory Judgment Guidance For ANDA Litigants
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Some Declaratory Judgment Guidance For ANDA Litigants
More informationUnited States Court of Appeals for the Federal Circuit
United States Court of Appeals for the Federal Circuit 01-1357, -1376, 02-1221, -1256 KNORR-BREMSE SYSTEME FUER NUTZFAHRZEUGE GMBH, v. Plaintiff-Cross Appellant, DANA CORPORATION, and Defendant-Appellant,
More informationCase 2:04-cv TJW Document 424 Filed 03/21/2007 Page 1 of 5
Case :04-cv-000-TJW Document 44 Filed 0/1/007 Page 1 of 5 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF TEXAS MARSHALL DIVISION O MICRO INTERNATIONAL LTD., Plaintiff, v. BEYOND INNOVATION
More informationFDA, PATENT TERM EXTENSIONS AND THE HATCH WAXMAN ACT. Dr.Sumesh Reddy- Dr. Reddys Lab Hyderabad-
FDA, PATENT TERM EXTENSIONS AND THE HATCH WAXMAN ACT Dr.Sumesh Reddy- Dr. Reddys Lab Hyderabad- FDA Regulatory approval-time and cost Focus of FDA approval process-safety and efficacy Difference between
More informationORDER GRANTING IN PART AND DENYING IN PART MOTION TO TRANSFER OR STAY
Pfizer Inc. et al v. Sandoz Inc. Doc. 50 Civil Action No. 09-cv-02392-CMA-MJW IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLORADO Judge Christine M. Arguello PFIZER, INC., PFIZER PHARMACEUTICALS,
More informationUPDATE ON CULPABLE MENTAL STATES AND RELATED ETHICAL AND PRIVILEGE IMPLICATIONS IN FEDERAL CIVIL LITIGATION. April 23, 2010
UPDATE ON CULPABLE MENTAL STATES AND RELATED ETHICAL AND PRIVILEGE IMPLICATIONS IN FEDERAL CIVIL LITIGATION April 23, 2010 David G. Barker and Scott C. Sandberg 1 The culpable mental state required for
More informationCase: 1:16-cv Document #: 1 Filed: 03/09/16 Page 1 of 13 PageID #:1 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION
Case: 1:16-cv-02988 Document #: 1 Filed: 03/09/16 Page 1 of 13 PageID #:1 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION TORRENT PHARMACEUTICALS LIMITED, and TORRENT PHARMA
More informationPOST-MEDIMMUNE DEVELOPMENTS REGARDING DECLARATORY JUDGMENT JURISDICTION
POST-MEDIMMUNE DEVELOPMENTS REGARDING DECLARATORY JUDGMENT JURISDICTION The Federal Circuit's Recent SanDisk and Teva Pharmaceuticals Decisions On March 26 and 30, the U.S. Court of Appeals for the Federal
More informationTECHNOLOGY & BUSINESS LAW ADVISORS, LLC
TECHNOLOGY & BUSINESS LAW ADVISORS, LLC www.tblawadvisors.com Fall 2011 Business Implications of the 2011 Leahy-Smith America Invents Act On September 16, 2011, the Leahy-Smith America Invents Act (AIA)
More informationTeva v. EISAI: What's the Real Controversy
Michigan Telecommunications and Technology Law Review Volume 18 Issue 1 2011 Teva v. EISAI: What's the Real Controversy Grace Wang University of Michigan Law School Follow this and additional works at:
More informationTHE UNITED STATES SUPREME COURT S DECISION IN EBAY V. MERCEXCHANGE: HOW IRREPARABLE THE INJURY TO PATENT INJUNCTIONS? RICHARD B. KLAR I.
THE UNITED STATES SUPREME COURT S DECISION IN EBAY V. MERCEXCHANGE: HOW IRREPARABLE THE INJURY TO PATENT INJUNCTIONS? RICHARD B. KLAR I. INTRODUCTION The United States Supreme Court s decision in ebay,
More informationAttachment C M AY Daniel J. Tomasch, Esq. Orrick, Herrington & Sutcliffe LLP 666 Fifth Ave. New York, NY Dear Mr.
DEPARTMENT OF Hr.PILTH & HUMAN SERVICES Health Service Public Food and Drug Administration R ockviue MD 20857 Daniel J. Tomasch, Esq. Orrick, Herrington & Sutcliffe LLP 666 Fifth Ave. New York, NY 10103
More informationUNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY
UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY WARNER CHILCOTT COMPANY, LLC, et al., Plaintiffs, Civil Action No. 11-6936 (SRC) v. OPINION & ORDER TEVA PHARMACEUTICALS USA, INC., Defendant. CHESLER,
More informationLicense Agreements and Litigation: Protecting Your Assets and Revenue Streams in the High-Tech and Life Science Industries
License Agreements and Litigation: Protecting Your Assets and Revenue Streams in the High-Tech and Life Science Industries January 21, 2010 *These materials represent our preliminary analysis based on
More information35 U.S.C. 286 Time limitation on damages.
35 U.S.C. 283 Injunction. The several courts having jurisdiction of cases under this title may grant injunctions in accordance with the principles of equity to prevent the violation of any right secured
More informationCase 1:18-cv IMK Document 250 Filed 08/30/18 Page 1 of 11 PageID #: 2905 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:18-cv-00226-IMK Document 250 Filed 08/30/18 Page 1 of 11 PageID #: 2905 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ALLERGAN SALES, LLC, FOREST LABORATORIES HOLDINGS, LTD.,
More informationCase 1:07-cv RMU Document 81 Filed 06/27/2007 Page 1 of 14 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
Case 1:07-cv-00579-RMU Document 81 Filed 06/27/2007 Page 1 of 14 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA MYLAN LABORATORIES, INC., et al., Plaintiffs, v. Civil Action No. 07-0579 (RMU
More informationAmerica Invents Act H.R (Became Law: September 16, 2011) Michael K. Mutter Birch, Stewart, Kolasch & Birch October 11-12, 2011
America Invents Act H.R. 1249 (Became Law: September 16, 2011) Michael K. Mutter Birch, Stewart, Kolasch & Birch www.bskb.com October 11-12, 2011 H.R. 1249 became law Sept. 16, 2011 - Overview first inventor
More informationCase 1:18-cv UNA Document 1 Filed 01/19/18 Page 1 of 14 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:18-cv-00117-UNA Document 1 Filed 01/19/18 Page 1 of 14 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE TEVA PHARMACEUTICALS INTERNATIONAL GMBH, CEPHALON, INC., and EAGLE
More informationPharmaceutical Product Improvements and Life Cycle Management Antitrust Pitfalls 1
Pharmaceutical Product Improvements and Life Cycle Management Antitrust Pitfalls 1 The terms product switching, product hopping and line extension are often used to describe the strategy of protecting
More informationHealth Care Law Monthly
Health Care Law Monthly February 2013 Volume 2013 * Issue No. 2 Contents: Copyright ß 2013 Matthew Bender & Company, Inc., a member of the Lexis- Nexis group of companies. All rights reserved. HEALTH CARE
More informationUnited States Court of Appeals for the Federal Circuit
United States Court of Appeals for the Federal Circuit 01-1369, -1370 MINNESOTA MINING AND MANUFACTURING COMPANY and RIKER LABORATORIES, INC., and ALPHAPHARM PTY. LTD., v. Plaintiffs-Appellants, Plaintiff-Appellant,
More informationInequitable Conduct Judicial Developments
Inequitable Conduct Judicial Developments Duke Patent Law Institute May 16, 2013 Presented by Tom Irving Copyright Finnegan 2013 Disclaimer These materials are public information and have been prepared
More informationCase 2:09-cv DMC-MF Document 17 Filed 04/20/2009 Page 1 of 28 : :
Case 2:09-cv-01302-DMC-MF Document 17 Filed 04/20/2009 Page 1 of 28 WINSTON & STRAWN LLP The Legal Center One Riverfront Plaza, 7th Floor Newark, New Jersey 07102 (973) 848-7676 James S. Richter Attorneys
More informationIN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE MEMORANDUM ORDER
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE THE JOHNS HOPKINS UNIVERSITY, Plaintiff, v. Civ. No. 15-525-SLR/SRF ALCON LABORATORIES, INC. and ALCON RESEARCH, LTD., Defendants. MEMORANDUM
More informationCase 1:10-cv JCJ Document 20 Filed 04/14/10 Page 1 of 12 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 110-cv-00137-JCJ Document 20 Filed 04/14/10 Page 1 of 12 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE MILLENNIUM PHARMACEUTICALS, INC. and SCHERING CORP., Plaintiffs, CIVIL ACTION
More informationIn ThIs Issue. What s in a Name? Quantifying the Economic Value of Label Information
AvAilAble Online Free to MeMbers www.fdli.org july/august 2015 A PublicAtion of the food And drug law institute In ThIs Issue What s in a Name? Quantifying the Economic Value of Label Information by Anthony
More informationInjunctive Relief in U.S. Courts
Injunctive Relief in U.S. Courts Elizabeth Stotland Weiswasser Patent Litigation Remedies Session/Injunctions April 13, 2012 Weil, Gotshal & Manges LLP Fordham IP Conference April 13, 2012 Footer / document
More informationALLERGAN, INC. and ALLERGAN SALES, INC., ALCON LABORATORIES, INC., ALCON RESEARCH, LTD., and ALCON UNIVERSAL, LTD.,
UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT 02-1449 ALLERGAN, INC. and ALLERGAN SALES, INC., Plaintiffs- Appellants, v. ALCON LABORATORIES, INC., ALCON RESEARCH, LTD., and ALCON UNIVERSAL, LTD.,
More informationUNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF INDIANA INDIANAPOLIS DIVISION ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )
UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF INDIANA INDIANAPOLIS DIVISION ELI LILLY AND COMPANY, v. Plaintiff, TEVA PARENTERAL MEDICINES, INC., APP PHARMACEUTICALS, LLC, PLIVA HRVATSKA D.O.O., TEVA
More information2010 Thomson Reuters. No Claim to Orig. US Gov. Works.
Page 1 United States Court of Appeals, Federal Circuit. CARACO PHARMACEUTICAL LABORATO- RIES, LTD., Plaintiff-Appellant, v. FOREST LABORATORIES, INC., Forest Laboratories Holdings, Ltd., and H. Lundbeck
More informationIff/]) FEB Gregory 1. Glover Pharmaceutical Law Group PC 900 Seventh Street, NW Suite 650 Washington, DC
DEPARTMENT OF HEALTH &. HUMAN SERVICES FEB 2 2 2011 Food and Drug Administration Rockville MD 20857 Gregory 1. Glover Pharmaceutical Law Group PC 900 Seventh Street, NW Suite 650 Washington, DC 20001-3886
More informationUNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT
UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT 02-1449 ALLERGAN, INC. and ALLERGAN SALES, INC., v. Plaintiffs-Appellants, ALCON LABORATORIES, INC., ALCON RESEARCH, LTD., and ALCON UNIVERSAL, LTD.,
More informationCase 1:13-cv JSR Document 252 Filed 06/30/14 Page 1 of 18
--------------------- ----- Case 1:13-cv-02027-JSR Document 252 Filed 06/30/14 Page 1 of 18 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ----------------------------------- x COGNEX CORPORATION;
More informationReasonable Royalties After EBay
Portfolio Media, Inc. 648 Broadway, Suite 200 New York, NY 10012 www.law360.com Phone: +1 212 537 6331 Fax: +1 212 537 6371 customerservice@portfoliomedia.com Reasonable Royalties After EBay Monday, Sep
More informationThe ITC's Potential Role In Hatch-Waxman Litigation
Portfolio Media. Inc. 111 West 19 th Street, 5th Floor New York, NY 10011 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com The ITC's Potential Role In Hatch-Waxman
More informationIssue Brief for Congress Received through the CRS Web
Order Code IB10105 Issue Brief for Congress Received through the CRS Web The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents Updated November 25, 2002 Wendy H. Schacht and
More informationSupreme Court of the United States
NO. 15-307 In the Supreme Court of the United States MYLAN PHARMACEUTICALS INC., v. Petitioner, APOTEX INC., Respondent. On Petition for Writ of Certiorari to the U.S. Court of Appeals for the Federal
More informationThe Changing Face of U.S. Patent Litigation
The Changing Face of U.S. Patent Litigation Presented by the IP Litigation Group of Simpson Thacher & Bartlett LLP October 2007 Background on Simpson Thacher Founded 1884 in New York City Now, over 750
More information2011 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative
2011 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative of clients 321 N. Clark Street, Suite 2800, Chicago,
More informationBNA s Patent, Trademark & Copyright Journal
BNA s Patent, Trademark & Copyright Journal Reproduced with permission from BNA s Patent, Trademark & Copyright Journal, 91 PTCJ 1505, 3/25/16. Copyright 2016 by The Bureau of National Affairs, Inc. (800-372-1033)
More informationUnited States Court of Appeals for the Federal Circuit
United States Court of Appeals for the Federal Circuit 02-1295 APOTEX, INC., v. Plaintiff-Appellant, TOMMY G. THOMPSON, Secretary of Health and Human Services, U.S. FOOD AND DRUG ADMINISTRATION, and LESTER
More informationCase 1:16-cv RBK-JS Document 1 Filed 06/30/16 Page 1 of 14 PageID: 1
Case 1:16-cv-03910-RBK-JS Document 1 Filed 06/30/16 Page 1 of 14 PageID: 1 John E. Flaherty Ravin R. Patel McCARTER & ENGLISH LLP Four Gateway Center 100 Mulberry St. Newark, NJ 07102 (973) 622-4444 Attorneys
More informationCase 1:09-cv UNA Document 1 Filed 07/13/2009 Page 1 of 17
Case 1:09-cv-00511-UNA Document 1 Filed 07/13/2009 Page 1 of 17 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ALLERGAN, INC., ALLERGAN USA, INC., ALLERGAN SALES, LLC, ENDO PHARMACEUTICALS
More informationPENDING LEGISLATION REGULATING PATENT INFRINGEMENT SETTLEMENTS
PENDING LEGISLATION REGULATING PATENT INFRINGEMENT SETTLEMENTS By Edward W. Correia* A number of bills have been introduced in the United States Congress this year that are intended to eliminate perceived
More informationPutting the Law (Back) in Patent Law
Putting the Law (Back) in Patent Law Some Thoughts on the Supreme Court s MedImmune Decision 21 March 2007 Joe Miller - Lewis & Clark Law School 1 Back in the Patent Game October 2005 Term Heard three
More informationPatent Infringement Claims and Opinions of Counsel Leveraging Opinion Letters to Reduce the Risks of Liability and Enhanced Damages
Presenting a 90-Minute Encore Presentation of the Teleconference with Email Q&A Patent Infringement Claims and Opinions of Counsel Leveraging Opinion Letters to Reduce the Risks of Liability and Enhanced
More informationAttorneys for Defendants Watson Laboratories, Inc. and Watson Pharmaceuticals, Inc.
Case 2:10-cv-00080-FSH -PS Document 15 Filed 03/01/10 Page 1 of 14 HELLRING LINDEMAN GOLDSTEIN & SIEGAL LLP Matthew E. Moloshok, Esq. Robert S. Raymar, Esq. One Gateway Center Newark, New Jersey 07102-5386
More informationCase 1:16-cv UNA Document 1 Filed 03/31/16 Page 1 of 12 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:16-cv-00207-UNA Document 1 Filed 03/31/16 Page 1 of 12 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE GALDERMA LABORATORIES, L.P.; NESTLÉ SKIN HEALTH S.A.; and TCD
More informationWe have carefully considered the Petition.! For the reasons described below, the Petition is granted.
DEPARTMENT OF HEALTH &. HUMAN SERVICES... -------------_._- Food and Drug Administration Rockville MD 20857 JUN 17 2010. Pankaj Dave, Ph.D. Vice President, Regulatory Affairs Navinta LLC 1499 Lower Ferry
More informationINTELLECTUAL PROPERTY LAW ARTICLE
INTELLECTUAL PROPERTY LAW ARTICLE How the New Multi-Party Patent Infringement Rulings Written by Brian T. Moriarty, Esq., Deirdre E. Sanders, Esq., and Lawrence P. Cogswell, Esq. The very recent and continuing
More informationUnited States Court of Appeals for the Federal Circuit
United States Court of Appeals for the Federal Circuit 03-1541, 04-1137, -1213 EVIDENT CORPORATION, Plaintiff/Counterclaim Defendant- Appellant, and PEROXYDENT GROUP, v. CHURCH & DWIGHT CO., INC., Counterclaim
More informationINTELLECTUALPROPERTY OWNERS WHITE PAPER APPLICATION OF INDUCEDINFRINGEMENT LAW JANUARY 2013 IN PHARMACEUTICAL PATENT LITIGATION
INTELLECTUALPROPERTY OWNERS WHITE PAPER APPLICATION OF INDUCEDINFRINGEMENT LAW IN PHARMACEUTICAL PATENT LITIGATION JANUARY 2013 This paper was created by the authors for the Intellectual Property Owners
More informationUnited States Court of Appeals for the Federal Circuit
Case: 14-1282 Case: CASE 14-1282 PARTICIPANTS Document: ONLY 44 Document: Page: 1 43 Filed: Page: 05/30/2014 1 Filed: 05/30/2014 2014-1282, -1291 United States Court of Appeals for the Federal Circuit
More informationBalancing Burdens for Accused Infringers: How In Re Seagate Got it Right
DePaul Law Review Volume 58 Issue 4 Summer 2009: In Memoriam Professor James W. Colliton Article 8 Balancing Burdens for Accused Infringers: How In Re Seagate Got it Right Ryan Crockett Follow this and
More informationCase 3:15-cv MAS-LHG Document 1 Filed 04/06/15 Page 1 of 38 PageID: 1
Case 3:15-cv-02520-MAS-LHG Document 1 Filed 04/06/15 Page 1 of 38 PageID: 1 Liza M. Walsh, Esq. CONNELL FOLEY LLP 85 Livingston Avenue Roseland, New Jersey 07068-1765 (973) 535-0500 Of Counsel: William
More informationFed. Circ. Should Clarify Irreparable Harm In Patent Cases
Fed Circ Should Clarify Irreparable Harm In Patent Cases Law360, New York (December 02, 2013, 1:23 PM ET) -- As in other cases, to obtain an injunction in a patent case, the plaintiff is required to demonstrate,
More informationUnited States Court of Appeals for the Federal Circuit
United States Court of Appeals for the Federal Circuit 2009-1071 ELI LILLY AND COMPANY, Plaintiff-Appellee, v. TEVA PHARMACEUTICALS USA, INC., Defendant-Appellant. Charles E. Lipsey, Finnegan, Henderson,
More informationCase 1:10-cv UNA Document 1 Filed 10/05/10 Page 1 of 20
Case 1:10-cv-00852-UNA Document 1 Filed 10/05/10 Page 1 of 20 Case 1:10-cv-00852-UNA Document 1 Filed 10/05/10 Page 2 of 20 4. Plaintiff Allergan Sales, LLC is a corporation organized and existing under
More informationA Response to Chief Justice Roberts: Why Antitrust Must Play a Role in the Analysis of Drug Patent Settlements
A Response to Chief Justice Roberts: Why Antitrust Must Play a Role in the Analysis of Drug Patent Settlements Michael A. Carrier* The Supreme Court s decision in FTC v. Actavis, Inc. 1 has justly received
More informationIN THE UNITED STATES PATENT AND TRADEMARK OFFICE
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PETITION FOR RULEMAKING UNDER 5 U.S.C. 553(e) AND 35 U.S.C. 2(b)(2) TO CORRECT THE TEXT PLACED ON ISSUED PATENT COVER BINDERS TO REMOVE WRONG INFORMATION
More informationPHARMACEUTICAL LAW GROUP PC
in L PHARMACEUTICAL LAW GROUP PC AT THE INTERSECTION OF FDA REGULATION AND INTELLECTUAL PROPERTY 900 SEVENTH STREET, NW - SUITE 650 - WASHINGTON, DC 20001-3886 T 202 589 1780 F 202 318 2198 WWW.PHARMALAWGRP.COM
More informationPharmaceutical Patent Settlement Cases: Mixed Signals for Settling Patent Litigation
By Margaret J. Simpson Tel: 312 923-2857 Fax: 312 840-7257 E-mail: msimpson@jenner.com The following article originally appeared in the Spring 2004 issue of the Illinois State Bar Association s Antitrust
More informationCase 3:11-cv JAP -TJB Document 32 Filed 07/06/11 Page 1 of 19 PageID: 530 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY
Case 3:11-cv-03111-JAP -TJB Document 32 Filed 07/06/11 Page 1 of 19 PageID: 530 NOT FOR PUBLICATION UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY : NOSTRUM PHARMACEUTICALS, LLC, : : Plaintiff,
More informationCase 1:16-cv UNA Document 1 Filed 01/15/16 Page 1 of 13 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:16-cv-00015-UNA Document 1 Filed 01/15/16 Page 1 of 13 PageID #: 1 PROSTRAKAN, INC. and STRAKAN INTERNATIONAL S.á r.l., IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE v. Plaintiffs,
More informationCase 2:15-cv WHW-CLW Document 1 Filed 08/31/15 Page 1 of 145 PageID: 1
Case 2:15-cv-06541-WHW-CLW Document 1 Filed 08/31/15 Page 1 of 145 PageID: 1 Charles M. Lizza William C. Baton SAUL EWING LLP One Riverfront Plaza, Suite 1520 Newark, New Jersey 07102-5426 (973) 286-6700
More informationThe Royal Society of Chemistry IP Law Case Seminar: 2017 in the U.S.
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP The Royal Society of Chemistry IP Law Case Seminar: 2017 in the U.S. Anthony C. Tridico, Ph.D. 2017 1 Agenda U.S. Supreme Court news 2017 U.S. Court
More informationFish & Richardson Declaratory Judgment Post-Medimmune Presentation
Fish & Richardson Declaratory Judgment Post-Medimmune Presentation Where are we now? Jan. 9, 2007 Supreme Court decides MedImmune v. Genentech March 26, 2007 Federal Circuit decides SanDisk v. STMicroelectronics
More informationCase 3:16-cv MAS-LHG Document 1 Filed 09/16/16 Page 1 of 14 PageID: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY
Case 3:16-cv-05678-MAS-LHG Document 1 Filed 09/16/16 Page 1 of 14 PageID: 1 Liza M. Walsh Tricia B. O Reilly Katelyn O Reilly WALSH PIZZI O REILLY FALANGA LLP 1037 Raymond Boulevard, Suite 600 Newark,
More informationCase 1:16-cv UNA Document 1 Filed 04/07/16 Page 1 of 17 PageID #: 1 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ) ) ) ) ) ) ) ) )
Case 1:16-cv-00237-UNA Document 1 Filed 04/07/16 Page 1 of 17 PageID #: 1 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE FRESENIUS KABI USA, LLC, Plaintiff, v. MAIA PHARMACEUTICALS, INC., Defendant.
More informationHatch-Waxman Patented v. Generic Drugs: Regulatory, Legislative and Judicial Developments
Santa Clara High Technology Law Journal Volume 20 Issue 3 Article 4 January 2004 Hatch-Waxman 2003 - Patented v. Generic Drugs: Regulatory, Legislative and Judicial Developments Richard J. Smith Follow
More informationSupreme Court of the United States
No. 10-844 IN THE Supreme Court of the United States CARACO PHARMACEUTICAL LABORATORIES, LTD., et al., Petitioners, v. NOVO NORDISK A/S, et al., Respondents. On Writ of Certiorari to the United States
More informationCase 8:14-cv GJH Document 14 Filed 08/19/14 Page 1 of 11 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND
Case 8:14-cv-02662-GJH Document 14 Filed 08/19/14 Page 1 of 11 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND HOSPIRA, INC., ) ) Plaintiff, ) ) v. ) CIVIL ACTION NO. ) 8:14-cv-02662-GJH
More informationCase 1:17-cv UNA Document 1 Filed 10/20/17 Page 1 of 8 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:17-cv-01481-UNA Document 1 Filed 10/20/17 Page 1 of 8 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE FOREST LABORATORIES, LLC, FOREST LABORATORIES HOLDINGS, LTD., ALLERGAN
More informationAmerica Invents Act (AIA) The Patent Reform Law of 2011 Initial Summary
PRESENTATION TITLE America Invents Act (AIA) The Patent Reform Law of 2011 Initial Summary Christopher M. Durkee James L. Ewing, IV September 22, 2011 1 Major Aspects of Act Adoption of a first-to-file
More informationPay-for-Delay Settlements: Antitrust Violation or Proper Exercise of Pharmaceutical Patent Rights?
Pay-for-Delay Settlements: Antitrust Violation or Proper Exercise of Pharmaceutical Patent Rights? By Kendyl Hanks, Sarah Jacobson, Kyle Musgrove, and Michael Shen In recent years, there has been a surge
More informationEnjoining Life Sciences Competition: A Review and Discussion
Litigation Webinar Series Enjoining Life Sciences Competition: A Review and Discussion Betsy Flanagan Principal, Minneapolis, MN Greg Booker Principal, Wilmington, DE 1 Welcome Litigation Series Key Developments
More informationCase 1:11-cv PAC Document 25 Filed 10/14/11 Page 1 of 11
Case 1:11-cv-02541-PAC Document 25 Filed 10/14/11 Page 1 of 11 USDC SDNY DOCUMENT UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ------------------------------------------------------------------X
More informationFDA Regulatory February 18, 2015
ROPES & GRAY ALERT FDA Regulatory February 18, 2015 Orange Book Patent Listing and Patent Certifications: Key Provisions in FDA s Proposed Regulations Implementing the Medicare Modernization Act of 2003
More informationThe Truth About Injunctions In Patent Disputes OCTOBER 2017
The Truth About Injunctions In Patent Disputes OCTOBER 2017 nixonvan.com Injunction Statistics Percent of Injunctions Granted 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Injunction Grant Rate by PAE Status
More informationCase 1:09-md SLR Document 273 Filed 05/20/11 Page 1 of 7 PageID #: 5592
Case 1:09-md-02118-SLR Document 273 Filed 05/20/11 Page 1 of 7 PageID #: 5592 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE IN RE: CYCLOBENZAPRINE ) HYDROCHLORIDE EXTENDED ) Civ. No.
More informationJurisdiction In Hatch-Waxman Actions Against Foreign Entities
Jurisdiction In Hatch-Waxman Actions Against Foreign Entities Law360, New York (October 19, 2015, 10:36 AM ET) - The 2014 U.S. Supreme Court decision in Daimler AG v. Bauman[1] has increased challenges
More informationBroadcam Corp. v. Qualcomm Inc. 543 F.3D 683 (Fed. Cir. 2008)
DePaul Journal of Art, Technology & Intellectual Property Law Volume 19 Issue 1 Fall 2008 Article 9 Broadcam Corp. v. Qualcomm Inc. 543 F.3D 683 (Fed. Cir. 2008) Ryan Schermerhorn Follow this and additional
More informationDetailed Table of Contents
Detailed Table of Contents Main Volume Supplement Preface... vii vii Acknowledgments... ix xi Summary Table of Contents... xiii xiii I. Patent Infringement Liability 1. Direct and Indirect Infringement
More informationPost-EBay: Permanent Injunctions, Future Damages
Portfolio Media, Inc. 648 Broadway, Suite 200 New York, NY 10012 www.law360.com Phone: +1 212 537 6331 Fax: +1 212 537 6371 customerservice@portfoliomedia.com Post-EBay: Permanent Injunctions, Future Damages
More informationCase 1:12-cv SLR Document 18 Filed 08/27/12 Page 1 of 17 PageID #: 71 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:12-cv-00809-SLR Document 18 Filed 08/27/12 Page 1 of 17 PageID #: 71 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE PFIZER INC., WYETH LLC, WYETH PHARMACEUTICALS INC., and PF PRISM
More informationWILLFUL PATENT INFRINGEMENT: THEORETICALLY SOUND? A PROPOSAL TO RESTORE WILLFUL INFRINGEMENT TO ITS PROPER PLACE WITHIN PATENT LAW
WILLFUL PATENT INFRINGEMENT: THEORETICALLY SOUND? A PROPOSAL TO RESTORE WILLFUL INFRINGEMENT TO ITS PROPER PLACE WITHIN PATENT LAW STEPHANIE PALL The patent system encourages public disclosure of information
More informationCase 1:14-cv IMK Document 125 Filed 06/16/14 Page 1 of 21 PageID #: 1959
Case 1:14-cv-00075-IMK Document 125 Filed 06/16/14 Page 1 of 21 PageID #: 1959 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF WEST VIRGINIA MYLAN PHARMACEUTICALS, INC., Plaintiff, WATSON
More informationCase 1:07-cv RMU Document 71-2 Filed 05/08/2007 Page 1 of 6. ANDA , Amlodipine Besylate Tablets, 2.5 mg, 5 mg, and 10 mg.
Case 1:07-cv-00579-RMU Document 71-2 Filed 05/08/2007 Page 1 of 6 DEPARTMENT OF HEALTH & HUMAN SERVICES ANDA 76-719, Amlodipine Besylate Tablets, 2.5 mg, 5 mg, and 10 mg. SENT BY FACSIMILE AND U.S. MAIL
More information